EnGeneIC Limited

Investment Highlights

Company Overview

EnGeneIC is a clinical-stage biopharmaceutical company focused on advancing its proprietary EDV® (EnGeneIC Dream Vector) nanocell technology for oncology and infectious disease applications. The EDV™ nanocell is the foundation of a first-in-class antibody nanocell drug conjugate platform for delivering a range of therapeutic payloads - drugs, siRNAs, miRNAs, adjuvants – via antibody-targeting a cancer cell’s surface, with minimal toxicity.

For cancer applications, the EDV technology enables delivery of the most potent chemotherapeutic agents, effectively overcoming drug-resistance and killing tumor cells, while simultaneously stimulating the patient’s immune system, allowing a potent anti-tumor response. EnGeneIC is now entering Phase IIa clinical trials in Australia and the USA in patients with intractable, low survival cancers, including patients with metastatic pancreatic cancer.

Products 

EnGeneIC's technology platform, EDV™ utilizes antibody-targeted, non-living "nanocells" to release their payload directly into tumor cells. In doing so, EDV™ nanocells allow the use of very potent drugs and are far less toxic, while also offering a potential new means for treating drug-resistant cancers and stimulating a potent anti-tumor immune response.

Loading & Targeting EDV's

Drug or siRNA or miRNA packaging in EDV™ nanocells
A single 400nm EDV™ can be packed with up to 1 million molecules of an anticancer drug such as Doxorubicin or the extremely potent derivative of nemorubicin, PNU159682, which is unable to be used systemically as a clinical chemotherapeutic due to its severe toxicity. Animal and human studies have provided positive safety and efficacy data.

In addition, regulatory genetic molecules (siRNA/miRNA) can be loaded in therapeutically significant concentrations as demonstrated in animal and human trials.

Specific Targeting of EDVs to tumours
Payload-packaged EDV™ is coated with a bispecific antibody which attaches through antibody-antigen interaction to the EDV™ at one end and has specificity to cancer cells on the other end. The tumor targeting antibody can be changed depending on the type of cancer.